HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Rose Sheet

Executive Summary

Research Institute for Fragrance Materials "strives to be the international leader for the safe use of fragrance ingredients, and has ongoing research programs in the areas of fragrance allergy, human health effects, respiratory safety and environmental impact," President Ladd Smith states in a letter to the editor of Environmental Health Perspectives published in the November issue of the journal. Smith responds to letter on the toxicity of fragrances by Luke Curtis of the University of Illinois School of Public Health published in June stating the need for more research on the health effects of artificial flavors and fragrances. Vast majority of 4,000 chemicals used in artificial fragrances have not been tested for human toxicity, according to Curtis. Smith, however, points to more recent studies on fragrances and notes RIFM's research is modeled after the National Academy of Sciences' risk assessment method and that research results and safety evaluations are published in peer-reviewed journals...

You may also be interested in...

Neuroscience Challenges Oncology For Top Spot In CDER’s 2019 Novel Approvals

Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.

In Case You Missed It … News On China Patents, EMA Chief, And More

We clean out your Martin Luther King Day inbox so you don't have to.

At Muted J.P. Morgan, Focus Is Execution, But US Pricing Is Persistent Overhang

Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts